浩欧博 | 上市三年,业绩下滑,易“主”脱困

浩海投研Pro
06 Dec 2024

全文1709字,阅读约需5分钟,帮我划重点划重点01浩欧博(688656)披露控制权拟变更公告,实际控制权将正式易主中国生物制药。02自2021年上市以来,浩欧博收入增速下滑,增收但不增利,展业困难。03公司面临高营销和高管理费用问题,导致盈利能力每况愈下。04为此,浩欧博开始探索新业务,如脱敏药,但进口产品的推广和销售面临挑战。以上内容由腾讯混元大模型生成,仅供参考作者/星空下的牛油果编辑/菠菜...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10